Merck Reports Five-Year KEYNOTE-048 Data for Keytruda in Head and Neck Cancer

Merck today presented five-year overall survival data from the Phase 3 KEYNOTE-048 trial evaluating Keytruda (pembrolizumab) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. The data showed that 23% of patients in the Keytruda monotherapy arm were alive at five years, compared to 16% in the EXTREME regimen arm.